Y Intercept Hong Kong Ltd Makes New $619,000 Investment in Septerna, Inc. $SEPN

Y Intercept Hong Kong Ltd acquired a new position in shares of Septerna, Inc. (NASDAQ:SEPN) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 25,770 shares of the company’s stock, valued at approximately $619,000. Y Intercept Hong Kong Ltd owned 0.06% of Septerna at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Strs Ohio increased its position in shares of Septerna by 17.8% in the 1st quarter. Strs Ohio now owns 17,200 shares of the company’s stock valued at $413,000 after acquiring an additional 2,600 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Septerna during the 4th quarter worth about $88,000. Seven Fleet Capital Management LP acquired a new stake in Septerna during the 4th quarter worth about $319,000. XTX Topco Ltd purchased a new stake in Septerna during the 4th quarter valued at about $650,000. Finally, VARCOV Co. purchased a new stake in Septerna during the 4th quarter valued at about $631,000.

Analyst Ratings Changes

A number of research firms recently commented on SEPN. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Septerna in a report on Wednesday, July 1st. JPMorgan Chase & Co. increased their price objective on shares of Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Stifel Nicolaus started coverage on shares of Septerna in a report on Friday, May 1st. They issued a “buy” rating and a $43.00 price target on the stock. Finally, Raymond James Financial increased their price target on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.89.

Insider Activity at Septerna

In other Septerna news, insider Samira Shaikhly sold 2,178 shares of Septerna stock in a transaction on Monday, June 29th. The shares were sold at an average price of $35.18, for a total value of $76,622.04. Following the completion of the transaction, the insider owned 793 shares of the company’s stock, valued at approximately $27,897.74. The trade was a 73.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the sale, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $4,240,247.06. The trade was a 2.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 48,494 shares of company stock worth $1,566,751. 5.80% of the stock is owned by company insiders.

Septerna Trading Down 4.4%

Septerna stock opened at $34.36 on Tuesday. Septerna, Inc. has a 12 month low of $10.62 and a 12 month high of $38.04. The stock’s 50 day simple moving average is $31.41 and its two-hundred day simple moving average is $27.98. The firm has a market cap of $1.55 billion, a PE ratio of -42.42 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The firm had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. On average, equities research analysts forecast that Septerna, Inc. will post -1.59 EPS for the current year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.